The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program

American Heart Journal

Volumn 149, Issue 5, 2005, Pages 939-943

  Pocock, Stuart ^a   Wang, Duolao ^a   Wilhelmsen, Lars ^b   Hennekens, Charles H ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN;

CLINICAL PRACTICE; DEATH; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; HEART FAILURE; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT OUTCOME;

EID: 19344371548     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.10.038     Document Type: Article

References (9)

1. M.A. Pfeffer, K. Swedberg, and C.B. Granger Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme Lancet 362 2003 759 766
2. J.J.V. McMurray, J. Östergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added Trial Lancet 362 2003 767 771
3. C.B. Granger, J.J.V. McMurray, and S. Yusuf Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative Trial Lancet 362 2003 772 776
4. S. Yusuf, M.A. Pfeffer, and K. Swedberg Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
5. S. Pocock, and C.D. Furberg Procedures of data and safety monitoring committees Am Heart J 141 2001 289 294
6. R. Peto, M.C. Pike, and P. Armitage Design and analysis of randomised clinical trials requiring prolonged observation of each patient: I. Introduction and design Br J Cancer 34 1976 585 612
7. R.S. McKelvie, J.L. Rouleau, and M. White Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure Eur Heart J 24 2003 1727 1734
8. S.J. Pocock, and I. White Trials stopped early: too good to be true Lancet 353 1999 943 944
9. SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302